NCT00560430|CompletedPhase 3
Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients
METATEL
Loading search results
METATEL
Sponsor study identifier
Secondary identifiers
interventional
56
1 country
2
Study Start
November 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2009
Actual (reported)Study Completion
October 2009
Actual (reported)A number of studies have shown that certain blood-pressure medications such as ACE-inhibitors and angiotensin-II-receptor blockers (ARB) can reduce the incidence of diabetes mellitus type 2. This protocol will evaluate whether inflammatory mechanisms mediate this effect. The investigators therefore will investigate the effect of telmisartan, a potent ARB, on lipid metabolism, glucose metabolism and inflammation in patients with the metabolic syndrome. Specific parameters will be tested before treatment and after 3 months of treatment. Placebo will be compared to 2 different doses of telmisartan per day.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2007
Date type not reportedThis date has not been verified as actual or estimated.
November 16, 2007
Actual (reported)November 19, 2007
Actual (reported)September 2009
Actual (reported)October 2009
Actual (reported)change in IL-6
14 weeks
change in fasting lipids;
14 weeks
change in postprandial lipid metabolism
14 weeks
change in inflammatory parameters
14 weeks
change in glucose metabolism
14 weeks
Telmisartan 80 mg/d
Telmisartan 160 mg/d
placebo
80 mg per day, orally, weeks 1-14
80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
Center for Cardiovascular Research, University Berlin
Berlin, 10115, Germany
Med. Dept. 2, University Munich
Munich, 81377, Germany
Klaus G Parhofer, MD
Ludwig-Maximilians - University of Munich
56 participants (actual enrollment reported by the registry).
First Submitted
November 16, 2007
First Posted
November 19, 2007
Study Start
November 2007
Date type not reportedThis date has not been verified as actual or estimated.
Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg
placebo; orally weeks 1-14
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
September 2009
Actual (reported)Study Completion
October 2009
Actual (reported)Last Updated
July 15, 2010
Record last verified: 2008-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: